<DOC>
	<DOCNO>NCT00569062</DOCNO>
	<brief_summary>GW856553 novel compound , currently development treatment Major Depressive Disorder ( MDD ) , indication . GW856553 inhibit protein responsible production pro-inflammatory molecule , call cytokine . Increased blood level molecule see population MDD patient apparent subject severe symptom , psychomotor retardation loss energy . Aim present study ass whether GW856553 , inactivate protein , able suppress production cytokine , ultimately relieve depression symptom . In study GW856553 placebo give MDD patient 7.5md twice daily 6 week .</brief_summary>
	<brief_title>A Study GW856553X For Treatment Depression</brief_title>
	<detailed_description>A randomised , double-blind , placebo-controlled study explore antidepressant property P38a kinase inhibitor GW856553X 15mg compare placebo subject Major Depressive Disorder exhibit symptom loss energy interest , psychomotor retardation , six week treatment period .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>Male female = 18 year age &lt; 60 year , routine laboratory result within normal range , Body Mass Index within range 18.535.0 kg/m2 inclusive . Subject must least one previous major depressive episode diagnosis MDD his/her history , successful pharmacological treatment episode , currently experience recurrence MDD presently unmedicated . Subjects must meet diagnosis episode Major Depressive Disorder past 12 week great 24 month . The subject history liver disease . The subject significant cardiac , pulmonary , metabolic , renal , hepatic gastrointestinal condition , opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial . The subject history autoimmune disease . The subject active infectious disease , include active tuberculosis history active tuberculosis . The subject history malignancy , except surgically cure basal cell carcinoma female cure cervical carcinoma ( &gt; 2 yrs prior ) . The subject history HIV immunosuppressive disease . The subject uncontrolled diabetes . The subject pregnant nursing . Subject contact adult daily basis ( i.e. , subject live least one adult subject adult contact daily basis ) . Subject initiated psychotherapy within three month prior Screening visit , plan initiate psychotherapy trial . Subject receive electroconvulsive therapy transcranial magnetic stimulation vagal nerve stimulation within six month prior Screening . The subject currently receive chronic biological pharmacologic antiinflammatory therapy ; interferon therapy dose receive within 6 month prior randomisation . Subjects donate unit blood within previous month intend donate month complete study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Psychomotor retardation ,</keyword>
	<keyword>Major Depressive Disorder ( MDD ) ,</keyword>
	<keyword>GW856553 ,</keyword>
	<keyword>cytokine</keyword>
</DOC>